Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.350
-0.090 (-2.03%)
Aug 14, 2025, 11:40 AM - Market open
Monte Rosa Therapeutics Revenue
Monte Rosa Therapeutics had revenue of $23.19M in the quarter ending June 30, 2025, with 394.01% growth. This brings the company's revenue in the last twelve months to $177.99M, up 2,990.57% year-over-year. In the year 2024, Monte Rosa Therapeutics had annual revenue of $75.62M.
Revenue (ttm)
$177.99M
Revenue Growth
+2,990.57%
P/S Ratio
2.05
Revenue / Employee
$1,328,254
Employees
134
Market Cap
268.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GLUE News
- 7 days ago - Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 24 days ago - Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire
- 5 weeks ago - Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 3 months ago - Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer - GlobeNewsWire
- 5 months ago - Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript - Seeking Alpha